公开(公告)号：US06737410B1

公开(公告)日：2004-05-18

申请号：US09678554

申请日：2000-10-04

Applicant: Annette Marian Doherty ,  Daniele Marie Leonard ,  Dennis Joseph McNamara ,  Kevon Ray Shuler

Inventor： Annette Marian Doherty ,  Daniele Marie Leonard ,  Dennis Joseph McNamara ,  Kevon Ray Shuler

IPC: C07K506

CPC classification number: C07K5/06139 ,  C07K5/06191

Abstract: The present invention provides compounds having the structure represented by Formula I: and methods of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.

Abstract translation: 本发明提供具有由式I表示的结构的化合物以及治疗癌症，再狭窄，动脉粥样硬化或银屑病或预防再狭窄的方法，以及包含式I化合物和药学上可接受的载体的药物组合物。

公开(公告)号：US06559142B2

公开(公告)日：2003-05-06

申请号：US10071662

申请日：2002-02-08

Applicant: Patrick Michael O'Brien ,  William Chester Patt ,  Joseph Armand Picard ,  Kevon Ray Shuler ,  Drago Robert Sliskovic

Inventor： Patrick Michael O'Brien ,  William Chester Patt ,  Joseph Armand Picard ,  Kevon Ray Shuler ,  Drago Robert Sliskovic

IPC: C07D27912

CPC classification number: C07D417/12 ,  C07D279/12 ,  C07D417/14

Abstract: Matrix metalloproteinase inhibitors are tricyclic substituted cyclic sulfonamides of the formula or a pharmaceutically acceptable salt thereof wherein R1 and R2 include hydrogen, alkyl, and substituted alkyl; R3 and R4 include hydrogen, halo, and alkyl; X is OH or NHOH, V is O, S, SO2, NR5, or CH2, R5 is a hydrogen or alkyl, and Z is (CH2)n, wherein n is an integer from 0 to 2.

Abstract translation: 基质金属蛋白酶抑制剂是下式的三环取代的环状磺酰胺或其药学上可接受的盐，其中R 1和R 2包括氢，烷基和取代的烷基; R3和R4包括氢，卤素和烷基; X是OH或NHOH，V是O，S，SO2，NR5或CH2，R5是氢或烷基，Z是（CH2）n，其中n是0-2的整数。

公开(公告)号：US06881743B2

公开(公告)日：2005-04-19

申请号：US10071073

申请日：2002-02-08

Applicant: Nicole Chantel Barvian ,  David Thomas Connor ,  Patrick Michael O'Brien ,  Daniel Fred Ortwine ,  William Chester Patt ,  Kevon Ray Shuler ,  Michael William Wilson

Inventor： Nicole Chantel Barvian ,  David Thomas Connor ,  Patrick Michael O'Brien ,  Daniel Fred Ortwine ,  William Chester Patt ,  Kevon Ray Shuler ,  Michael William Wilson

IPC: A61K20060101 ,  A61K31/44 ,  A61K31/4427 ,  A61P20060101 ,  A61P9/00 ,  A61P9/04 ,  A61P19/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D213/80 ,  C07D213/81 ,  C07D213/82 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D521/00 ,  A61K31/4412 ,  C07D405/12

CPC classification number: C07D213/80 ,  C07D213/81 ,  C07D213/82 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3, E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, n is an integer of from 0 to 6.

Abstract translation: 选择性MMP-13抑制剂是下式的吡啶衍生物或其药学上可接受的盐，其中：R 1和R 2独立地是氢，卤素，羟基，C

公开(公告)号：US06265382B1

公开(公告)日：2001-07-24

申请号：US09331876

申请日：1999-06-28

Applicant: Annette Marian Doherty ,  Daniele Marie Leonard ,  Dennis Joseph McNamara ,  Kevon Ray Shuler

Inventor： Annette Marian Doherty ,  Daniele Marie Leonard ,  Dennis Joseph McNamara ,  Kevon Ray Shuler

IPC: C07K506

CPC classification number: C07K5/06139 ,  A61K38/00 ,  C07K5/06147

Abstract: The present invention provides compounds having the structure represented by formula (I). Also provided is a method of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compound of formula (I).

Abstract translation: 本发明提供具有由式（I）表示的结构的化合物。 还提供了治疗癌症，再狭窄，动脉粥样硬化或牛皮癣或预防再狭窄的方法，以及包含式（I）化合物的药物组合物。